By proceeding, you agree to our Terms of Use and Privacy Policy.
Maximize the Clinical & Commercial Opportunity of the Adenosine-Pathway as a Second-Generation Immuno-Oncology Target A plethora of showstopping clinical trial data readouts are being met with refreshed excitement, enthusiasm and R&D investment for adenosine-pathway targets, one of the most validated and established oncology pathways.
Learn about targeting adenosine-mediated immunosuppression via cd39, a2a receptor, sequencing of combinations, as also lessons learnt from clinical trial data.
Enjoy and get to explore the beautiful city of Boston as the Adenosine-Pathway Targeted Cancer Immunotherapy Summit will take place at the Bostonian!
Get the opportunity to connect with and gain insights from cancer experts like Arabella Young, Bin Zhang, Carine Paturel, Daniel DiRenzo and Kavitha Yaddanapudi.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Tarus Therapeutics is a biotechnology company focused on nucleotide metabolism in cancer. The company’s lead programs target the immunosuppressive adenosine pathway in the tumor microenvironment (TME) for the treatment of resistant cancers.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.